TerminatedPhase 1/2

Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies

Stopped: business reason

United States, France79 participantsStarted 2017-12-05

Plain-language summary

This is a phase I/II, non randomized, open-label, dose escalation study to investigate the safety, tolerability and preliminary efficacy of CB-103.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✕. Medical History
✕. Patients with symptomatic CNS metastases (neurologically unstable or requiring increasing doses of steroids to control their CNS disease)
✕. Hypersensitivity to any of the excipients of CB-103
✕. Patients with unresolved nausea, vomiting, or diarrhoea of CTCAE grade \> 1
✕. Impairment of GI function or presence of GI disease that may significantly alter the absorption of CB-103
✕. History of second or other primary cancer with the exception of:
✕. Exclusionary concurrent medical conditions Impaired cardiac function or clinically significant cardiac diseases.
✕. Prior Therapy

Dose Limiting Toxicity (DLT)

Timeframe: 28 days

NCT IDNCT03422679

SponsorCellestia Biotech AG

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-11-11

Results submitted2023-10-23